Pfizer announced that WHO granted an expansion to the prequalification of Pfizer’s pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to include adults 50 years of age and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the vaccine. Luis Jodar, vice president, Vaccines, Global, Medicines Development Group and Scientific Affairs, Pfizer, said, “This expanded designation will allow for broader global access to the vaccine and provide the opportunity for a new prevention option for adults 50 years of age and older in developing nations.”

http://www.businesswire.com/news/home/20120911005783/en/World-Health-Organization-Grants-Expansion-Prequalification-Prevenar